Strides Shasun Limited has  received approval from the United States Food & Drug Administration (USFDA) for Ibuprofen Tablets USP, 200 mg (OTC). The product will be marketed by Strides Pharma Inc in the US Market under its OTC brand Nuprin.

According to IRi data, the US market for Ibuprofen tablets USP 200 mg (OTC) is approximately US$ 520 million. The approval further strengthens company’s fast growing global OTC franchise.

Ibuprofen is used to relieve pain from various conditions such as headache, dental pain, muscle aches  or arthritis. It is also used to reduce fever and to relieve minor aches and pain due to the common cold or flu. Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID).

The Bengaluru-based Strides Shasun has four business vertical: Regulated Markets, Emerging Markets, Institutional Business and Active Pharmaceutical Ingredients.